Who are Relugolix Combination Therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lupron, Micronor, Lupron Depot, Leuprolide acetate in depot suspension, LhRH-antagonist, GnRh agonist +1500E hCG.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/relugolix-combination-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Relugolix Combination Therapy — Competitive Intelligence Brief

Relugolix Combination Therapy (Relugolix Combination Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH antagonist. Area: Oncology.

phase 3 GnRH antagonist GnRH receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Relugolix Combination Therapy (Relugolix Combination Therapy) — Sumitomo Pharma Switzerland GmbH. Relugolix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to rapid reduction of testosterone and estrogen levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Relugolix Combination Therapy TARGET	Relugolix Combination Therapy	Sumitomo Pharma Switzerland GmbH	phase 3	GnRH antagonist	GnRH receptor
Lupron	leuprorelin	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Micronor	norethisterone	Johnson & Johnson	marketed	Progestin	GnRH receptors	1962-01-01
Lupron Depot	Lupron Depot	University of Michigan Rogel Cancer Center	marketed	GnRH agonist	GnRH receptor
Leuprolide acetate in depot suspension	Leuprolide acetate in depot suspension	Colorado Center for Reproductive Medicine	marketed	GnRH agonist	GnRH receptor
LhRH-antagonist	LhRH-antagonist	Turku University Hospital	marketed	GnRH/LhRH antagonist	GnRH receptor (LhRH receptor)
GnRh agonist +1500E hCG	GnRh agonist +1500E hCG	AZ Jan Palfijn Gent	marketed	GnRH agonist with hCG supplementation	GnRH receptor; LH receptor (via hCG)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-22 — Lupron · 9617303 · US
2031-02-05 — Lupron · 8921326 · US

Sponsor landscape (GnRH antagonist class)

Jiangsu HengRui Medicine Co., Ltd. · 2 drugs in this class
Instituto Valenciano de Infertilidad, IVI VALENCIA · 2 drugs in this class
AEterna Zentaris · 2 drugs in this class
El Shatby University Hospital for Obstetrics and Gynecology · 1 drug in this class
Eugonia · 1 drug in this class
Instituto de Investigacion Sanitaria La Fe · 1 drug in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class
Rabin Medical Center · 1 drug in this class
Sumitomo Pharma Switzerland GmbH · 1 drug in this class
University of Edinburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Relugolix Combination Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/relugolix-combination-therapy. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab